DiscoveryBioMed Developing A New Small Molecule Monotherapy For Cystic Fibrosis Patients

DiscoveryBioMed, Inc. (DMB) has discovered and is currently developing a new class of small molecule monotherapy that utilizes the pathophysiological features of cystic fibrosis and works on two drug targets. Continue reading DiscoveryBioMed Developing A New Small Molecule Monotherapy For Cystic Fibrosis Patients